Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Journal article published in 2019 by
D. Santos Faria,
J. Tavares Costa,
M. Eusébio 
,
J. Leite Silva,
J. Ramos Rodrigues,
J. Sousa Neves,
Duarte Ac,
C. Lopes,
A. Valido,
J. Dinis,
J. Freitas,
Santos Mj
,
J. Leite Silva,
J. Ramos Rodrigues,
J. Sousa Neves,
Duarte Ac,
C. Lopes,
A. Valido,
J. Dinis,
J. Freitas,
Santos Mj
